Bridgebio Pharma Inc 's Cash & cash equivalent grew by 113.68 % in the Q3 2026 sequentially, faster than Current Liabilities, this led to improvement in Bridgebio Pharma Inc 's Quick Ratio to 1.57, Quick Ratio remained below Bridgebio Pharma Inc average.

Within Major Pharmaceutical Preparations industry 370 other companies have achieved higher Quick Ratio than Bridgebio Pharma Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 0 to 2163.

Explain Quick Ratio?
How much Cash & cash equivalents BBIO�s has?
What are BBIO�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

BBIO Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	351.17 %	406.47 %	513.5 %	86.51 %	55.59 %
Y / Y Cash & cash equivalent Change	138.23 %	-4.85 %	73.92 %	-13.75 %	142.54 %
Quick Ratio MRQ	1.57	0.81	1.15	2.04	2.98
BBIO's Total Ranking	# 2163	# 0	# 569	# 732	#
Seq. Current Liabilities Change	9.72 %	9.1 %	183.49 %	32.95 %	23.17 %
Seq. Cash & cash equivalent Change	113.68 %	-23.4 %	60.04 %	-9.05 %	-14.66 %

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 371
Healthcare Sector	# 669
Overall Market	# 2163

Quick Ratio Statistics
High	Average	Low
23.68	6.35	0.81
(Sep 30 2019)		(Jun 30 2026)

Financial Statements
Bridgebio Pharma Inc 's Current Liabilities	$ 977 Millions	Visit BBIO's Balance sheet
Bridgebio Pharma Inc 's Cash & cash equivalent	$ 1,539 Millions	Visit BBIO's Balance sheet
Source of BBIO's Sales		Visit BBIO's Sales by Geography

Cumulative Bridgebio Pharma Inc 's Quick Ratio

BBIO's Quick Ratio for the trailling 12 Months

BBIO Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	337.14 %	267.05 %	166.79 %	42.85 %	21.65 %
Y / Y Cash & cash equivalent TTM Growth	44.28 %	28.9 %	51.38 %	32.17 %	63.04 %
Quick Ratio TTM	1.27	1.31	1.96	3.11	3.86
Total Ranking TTM	# 3915	# 0	# 1908	# 2765	#
Seq. Current Liabilities TTM Growth	34.39 %	47.75 %	84 %	19.65 %	12.84 %
Seq. Cash & cash equivalent TTM Growth	30.86 %	-1.25 %	15.79 %	-3.57 %	16.91 %

Quick ratio ranking by company, industry and sector >> Back to BBIO Financial Strength Comparisons >> Go to Compare BBIO Quick Ratio to its Competitors

News about Bridgebio Pharma Inc Quick Ratio

BridgeBio Pharma Approves Equity Grants and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma Approves Equity Grants and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., July 05, 2024 - BridgeBio Pharma, a commercial-stage biopharmaceutical company focused on genetic diseases, has announced the approval of equity grants to 25 new employees. These grants are in the form of restricted stock units and amount to a total of 123,070 shares of the company s common stock. The compensation committee of BridgeBio s board of directors approved these grants on July 2, 2024.
Under the terms of the grants, one-fourth of the shares underlying each employee s restricted stock units will vest on August 16, 2025. Thereafter, one-twelfth of the remaining shares will vest on a quarterly basis, subject to the employees continued employment with the company. These awards were made under BridgeBio s Amended and Restated 2019 Inducement Equity Plan.

BridgeBio Pharma Receives $1.25 Billion Funding and Grants Inducement Stock Units to Drive Genetic Medicine Development

BridgeBio Pharma Secures Funding and Grants Inducement Stock Units to Expand Workforce
BridgeBio Pharma, a leading biopharmaceutical company, recently announced a significant development in its efforts to advance the treatment of genetic diseases and cancers. The company has secured up to $1.25 billion in capital from Blue Owl and CPP Investments, which will be used to accelerate the development and launch of genetic medicines. In addition, BridgeBio Pharma has granted inducement stock units to nineteen new employees, highlighting its commitment to expanding its talented workforce.
The funding includes $500 million in cash from Blue Owl and CPP Investments. In exchange, the two investors will receive a 5% royalty on future global net sales of acoramidis, one of BridgeBio Pharma s promising drugs. This injection of capital will provide the company with the necessary resources to further its research and development efforts, as well as support the launch of new genetic medicines.

On the trailing twelve months basis Due to rise in Current Liabilities in the Q3 2026 to $977.24 millions, cumulative Quick Ratio decreased to 1.27 below the average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 434 other companies have achieved higher Quick Ratio than Bridgebio Pharma Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 0 to 3915.

Explain Quick Ratio?
How much Cash & cash equivalents BBIO�s has?
What are BBIO�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 435
Healthcare Sector	# 889
Within the Market	# 3915

trailing twelve months Quick Ratio Statistics
High	Average	Low
10.97	3.83	1.25
(Jun 30 2020)		(Jun 30 2026)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Foghorn Therapeutics Inc	4.19	$ 156.222 Millions	$ 37.315 Millions
Revelation Biosciences Inc	3.92	$ 9.122 Millions	$ 2.328 Millions
Tonix Pharmaceuticals Holding Corp	3.87	$ 162.793 Millions	$ 42.026 Millions
Lyell Immunopharma Inc	3.83	$ 177.106 Millions	$ 46.271 Millions
Rapport Therapeutics Inc	3.68	$ 74.754 Millions	$ 20.302 Millions
Seaport Therapeutics Inc	3.60	$ 61.552 Millions	$ 17.106 Millions
Cytokinetics Incorporated	3.20	$ 1,130.021 Millions	$ 353.419 Millions
Elicio Therapeutics Inc	3.11	$ 30.900 Millions	$ 9.930 Millions
Harmony Biosciences Holdings inc	3.02	$ 771.138 Millions	$ 254.981 Millions
Phio Pharmaceuticals Corp	2.96	$ 10.609 Millions	$ 3.583 Millions
Zevra Therapeutics Inc	2.95	$ 122.148 Millions	$ 41.369 Millions
Pyxis Oncology Inc	2.79	$ 55.572 Millions	$ 19.942 Millions
Zenas Biopharma Inc	2.78	$ 177.778 Millions	$ 64.043 Millions
Ptc Therapeutics inc	2.74	$ 2,127.918 Millions	$ 776.076 Millions
Turn Therapeutics Inc	2.71	$ 9.433 Millions	$ 3.479 Millions
Beone Medicines Ltd	2.67	$ 5,955.905 Millions	$ 2,233.923 Millions
Biohaven Ltd	2.57	$ 161.125 Millions	$ 62.767 Millions
Ironwood Pharmaceuticals inc	2.49	$ 86.376 Millions	$ 34.733 Millions
Tg Therapeutics Inc	2.43	$ 632.004 Millions	$ 260.526 Millions
Adc Therapeutics Sa	2.42	$ 189.204 Millions	$ 78.125 Millions
Opko Health Inc	2.37	$ 384.036 Millions	$ 162.356 Millions
Pacira Biosciences inc	2.31	$ 295.577 Millions	$ 128.209 Millions
Dogwood Therapeutics inc	2.28	$ 4.948 Millions	$ 2.174 Millions
Ardelyx inc	2.23	$ 285.338 Millions	$ 127.805 Millions
Schrodinger Inc	2.20	$ 366.358 Millions	$ 166.292 Millions
Stoke Therapeutics Inc	2.19	$ 107.271 Millions	$ 48.977 Millions
Maravai Lifesciences Holdings Inc	2.14	$ 73.023 Millions	$ 34.160 Millions
Ernexa Therapeutics Inc	2.13	$ 5.575 Millions	$ 2.614 Millions
Madrigal Pharmaceuticals Inc	2.12	$ 962.387 Millions	$ 454.244 Millions
Puma Biotechnology Inc	2.09	$ 108.575 Millions	$ 51.971 Millions

Date modified: 2026-10-30T17:01:30+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.